# Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.

> **NCT03541083** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stichting Hemato-Oncologie voor Volwassenen Nederland** · enrollment: 71 (actual)

## Conditions studied

- ALL, Adult

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT03541083
- **Lead sponsor:** Stichting Hemato-Oncologie voor Volwassenen Nederland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-04
- **Primary completion:** 2020-11-30
- **Final completion:** 2026-12-15
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03541083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03541083, "Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03541083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*